PolyPid (PYPD) COO details stock option and share holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PolyPid Ltd. executive Ori Warshavsky, Chief Operating Officer – US, reports his direct holdings of company equity. He holds several employee stock options to buy Ordinary Shares at exercise prices ranging from 2.6700 to 23.0700 per share, with expiration dates from 2031-08-09 through 2035-05-12.
These option grants vest on various quarterly schedules or are already fully vested, as described in the footnotes, and he also directly holds 267 Ordinary Shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Warshavsky Ori
Role
Chief Operating Officer - US
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Employee Stock option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Employee Stock option (right to buy) — 1,333 shares (Direct);
Ordinary Shares — 267 shares (Direct)
Footnotes (1)
- The options were granted on November 9, 2020 and fully vested as of October 1, 2023. The options were granted on May 9, 2022 and vest on a quarterly basis beginning May 9, 2023 until May 9, 2026. The options were granted on August 9, 2021 and fully vested as of August 9, 2025. The options were granted on August 7, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2028. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2026. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2029. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2027.
FAQ
What does PolyPid (PYPD) COO Ori Warshavsky report in this Form 3?
Ori Warshavsky reports his existing equity interests in PolyPid. He discloses multiple employee stock options over Ordinary Shares and a direct holding of 267 Ordinary Shares, giving investors a snapshot of his current beneficial ownership position with the company.
What are the exercise prices and expirations of PolyPid (PYPD) options held by the COO?
The COO’s options carry exercise prices from 2.6700 to 23.0700. These options over Ordinary Shares expire on various dates, including 2031-08-09, 2032-05-09, 2033-02-10, 2033-08-07, 2034-05-06 and 2035-05-12, as disclosed in the holding details.
How do the vesting schedules work for the PolyPid (PYPD) options disclosed?
The options vest either fully on specific dates or quarterly over time. Some grants are already fully vested, while others vest on a quarterly basis beginning on dates such as May 9, 2023, August 7, 2024, May 6, 2024, and May 12, 2025, running over multi‑year periods.
Are the PolyPid (PYPD) stock options held by the COO direct or indirect interests?
All reported holdings are described as directly owned. Each option position and the 267 Ordinary Shares are listed with direct ownership, without any indication of trusts, LLCs, or other entities having voting or investment authority over these securities.
Polypid Ltd.
NASDAQ:PYPD
PYPD Rankings
PYPD Latest News
PYPD Latest SEC Filings
Mar 31, 2026
[6-K] PolyPid Ltd. Current Report (Foreign Issuer)